| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
We established serum sLR11 concentration as a biomarker of pulmonary hypertension and elucidated the mechanism of pulmonary arterial hypertension development using Sugen pulmonary hypertension model rat. In pulmonary arterial hypertension (40 cases), serum sLR11 concentration was 10.9 ng / ml, which was significantly increased compared with the normal control group. Although there was no significant difference between the groups in the WHO functional classification, the 6 minute walking distance and the serum sLR11 concentration were positively correlated, suggesting that sLR11 might be an indicator of severity. In animal experiments, lung tissue LR11 protein expression increased to 1.8-fold at the early stage of disease, but was conversely reduced at the terminal stage. The above results suggest that LR11 may be a biomarker for pulmonary hypertension.
|
